Antibody Drug Conjugates in Glioblastoma - Is There a Future for Them?

Front Oncol · 2021 · PMC8678283 · PMID 34926242

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

a strong trendp=0.062so close (0.05 < p ≤ 0.1)

In this study, the combination of Depatux-M with temozolomide (TMZ) demonstrated a strong trend towards substantial benefit in overall survival compared to the chemotherapy arm (HR 0.71, p=0.062) ( 57 ).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.